Frontline BV+CHP and Brentuximab Vedotin Maintenance in CD30-Positive Peripheral T-Cell Lymphoma: A Real-World Study
Background/Objectives: We describe frontline brentuximab vedotin (BV) combined with cyclophosphamide, doxorubicin and prednisone (BV+CHP) and subsequent treatment in adults with CD30-positive peripheral T-cell lymphoma (PTCL). Methods: This single-center retrospective cohort included 18 adults treated with BV+CHP. We assessed end-of-induction response in the full cohort and recorded the first post-transplant response separately among recipients of autologous stem cell transplantation (ASCT). Overall survival (OS) and progression-free survival (PFS) were estimated from the first BV+CHP dose. Results: At the end of BV+CHP induction, before ASCT or BV maintenance where applicable, 15 of 18 patients achieved complete response (CR, 83.3%, 95% CI 58.6–96.4%). Three patients progressed during induction. Ten patients entered ASCT in first CR, and all remained in CR at the first post-ASCT assessment (median 62.5 days, range 55–70). Eight patients received BV maintenance, including five after ASCT. Three of the eight subsequently progressed and died. Median potential follow-up was 39.5 months by reverse Kaplan–Meier. The 24-month OS and PFS estimates were both 66.7% (95% CI 40.4–83.4%). Conclusions: The study describes outcomes after frontline BV+CHP in a small, histologically heterogeneous cohort. A comparative study is needed to determine whether BV maintenance affects relapse or survival.
Authors
- Sinem Namdaroğlu (ORCID: https://orcid.org/0000-0002-8074-7301)
- Semih Başçı (ORCID: https://orcid.org/0000-0003-4304-9245)
- Eray Arslan (ORCID: https://orcid.org/0000-0001-9127-6149)
- Hikmetullah Batgi (ORCID: https://orcid.org/0000-0002-5993-1403)
- Berna Güzel
- Kardelen Tayfur
Institutions
- Dokuz Eylül University (TR)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3390/jcm15229027
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00